Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04812431RecruitingPhase 1/Phase 2
Tested stem cell transplant therapy for severe spinal cord injury
This trial tests a cell transplant approach for people with a very severe spinal cord injury. It focuses first on safety and also looks for early signs the therapy may improve function.
Suwon, GyeonggidoAges 18–65 - NCT04818203RecruitingPhase 1/Phase 2
Autologous fibroblast injections for crow’s feet wrinkles
This study tests a safety and effectiveness approach for reducing crow’s feet (wrinkles at the outer corners of the eyes) using cells made from your own skin. You may be asked to stop other wrinkle treatments and have blood tests and injections at a specific skin area.
SeoulAges 19 years+ - NCT06474442RecruitingPhase 2
BD111 gene therapy for herpes simplex virus eye infection
This trial tests a new gene therapy called BD111 for people with a herpes simplex virus infection in the cornea (the clear front part of the eye). It aims to see if the treatment is safe and can help clear the virus, possibly improving vision.
Wenzhou, ZhejiangAges 18–70 - NCT07073833RecruitingPhase 1
IBR900 cell therapy for relapsed/refractory B-cell lymphoma
This trial tests a new cell therapy (IBR900) for people with a type of B-cell lymphoma that has come back or not responded to prior treatments. The therapy uses your own immune cells to target and kill the cancer cells.
Hangzhou, ZhejiangAges 18 years+ - NCT07070999RecruitingPhase 1/Phase 2
Gene therapy GB221 for infants with SMA type 1
This trial tests a new gene therapy called GB221 for infants with SMA type 1, a rare muscle-weakening disease. It aims to see if this treatment can improve muscle strength and development, and it is for babies who have not had prior gene therapy.
Porto Alegre, Rio Grande do SulAges 2 weeks–1 year - NCT07058662RecruitingPhase 1/Phase 2
Gene therapy study for Duchenne muscular dystrophy in boys 4-8
This study tests a new gene therapy called BBM-D101 for boys with Duchenne muscular dystrophy. The goal is to see if it is safe and can help improve muscle function. It is for boys aged 4 to 8 who can still walk.
Beijing, Beijing MunicipalityAges 4–9 - NCT07055594RecruitingPhase 1/Phase 2
Study of SOA101 for advanced solid tumors
This trial tests a new drug called SOA101 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug is safe and if it can help shrink tumors.
TaichungAges 18 years+ - NCT07063251RecruitingEarly Phase 1
Gene therapy safety study for Stargardt disease in teens
This study tests a new gene therapy called HG005 for Stargardt disease in young people aged 6 to 17. It aims to see if the treatment is safe and tolerable, and how well it works.
ShanghaiAges 6–17 - NCT06988670RecruitingPhase 2
Testing EXT608 for adults with hypoparathyroidism
This trial tests a new medicine called EXT608 for adults with hypoparathyroidism. It aims to see if this medicine can help manage calcium levels better than current treatments.
Buenos Aires, Buenos Aires F.D.Ages 18–65 - NCT07048054RecruitingPhase 1/Phase 2
Patch of fat cells for chronic leg ulcers
This trial tests a patch made from your own fat cells (called TrophiPatch) to see if it helps heal chronic leg ulcers. It is for people with venous leg ulcers or diabetic foot ulcers that are not healing well with standard care.
GenevaAges 18 years+ - NCT07044128Recruiting
Testing a new electronic stethoscope for heart murmur checks
This study is testing a new electronic stethoscope (called Keikku) to see if it works well and is safe for checking heart murmurs in children and adults who are not in an emergency situation. If it works, it could give doctors a better tool for evaluating heart sounds.
LimaAges Up to 99 years - NCT07007637Enrolling by invitationPhase 3
Long-Term Safety and Effectiveness of Sonelokimab for Hidradenitis Suppurativa
This study offers long-term treatment with an investigational biologic, sonelokimab, for people with moderate to severe hidradenitis suppurativa who finished an earlier sonelokimab study. The goal is to see if sonelokimab remains safe and effective over time.
Birmingham, AlabamaAges 12 years+ - NCT06618313Recruiting
Testing JCXH-213 for B-cell lymphoma that returned or didn't respond
This trial tests a new treatment called JCXH-213 for people with B-cell non-Hodgkin lymphoma that came back or didn't get better after previous treatment. It aims to see if the treatment is safe and works against the cancer.
BeijingAges 18 years+ - NCT07002398RecruitingPhase 1/Phase 2
Gene therapy for Stargardt disease (VG801)
This trial tests a new gene therapy called VG801 for people with Stargardt disease, a genetic condition that causes vision loss. The treatment aims to improve or slow vision loss by delivering a working copy of the ABCA4 gene to the retina.
Shanghai, Shanghai MunicipalityAges 6 years+ - NCT06988488RecruitingPhase 1/Phase 2
Study of mezigdomide plus elranatamab for relapsed multiple myeloma
This trial tests a combination of two drugs, mezigdomide (a pill) and elranatamab (an injection), for people whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to find the best dose and see if the combination is safe and effective.
Birmingham, AlabamaAges 18 years+ - NCT06960395RecruitingPhase 1
Study of VIR-5525 alone or with pembrolizumab for advanced solid tumors
This trial tests a new drug called VIR-5525, either alone or combined with pembrolizumab (an immunotherapy), for people with advanced solid tumors that have not responded to other treatments or cannot undergo standard therapy. It focuses on certain cancer types and tumors with a specific genetic change (EGFR amplification).
Scottsdale, ArizonaAges 18 years+ - NCT06120582RecruitingPhase 1/Phase 2
Gene therapy safety study for severe hemophilia B
This study tests a new gene therapy called ANB-002 for men with severe hemophilia B (factor IX levels at or below 2%). The goal is to see if it's safe and how well it might help your blood clot normally.
HomyelAges 18 years+ - NCT06927297RecruitingPhase 1
Safety study of a mitochondrial vaccine for advanced solid tumors
This early-phase trial tests a new type of cancer vaccine designed to help your immune system attack tumors. It is for people with advanced solid tumors who have run out of standard options.
Chengdu, SichuanAges 18–75 - NCT06897930RecruitingPhase 1/Phase 2
Testing a new drug for adults with lupus
This trial tests an investigational drug called AZD0120 in adults with lupus that hasn't improved with standard treatments. The goal is to see if it's safe and works well for people with lupus-related organ problems.
San Francisco, CaliforniaAges 18–70 - NCT06898450RecruitingPhase 1/Phase 2
Study of new drug NDI-219216 for advanced solid tumors
This study tests a new drug called NDI-219216 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and can help shrink or control the cancer.
Los Angeles, CaliforniaAges 18–99 - NCT05027906RecruitingPhase 1/Phase 2
Study drug AT 1501 for first-time kidney transplant patients
This Phase 1/2 trial tests how safe AT 1501 is and how it works in people getting their first kidney transplant. It aims to improve transplant outcomes by targeting the immune system, while carefully watching for side effects and immune compatibility issues.
Cincinnati, OhioAges 18–100 - NCT06889701RecruitingPhase 1/Phase 2
Testing TNP-2092 for knee infection after joint replacement
This trial tests a new antibiotic, TNP-2092, given as a shot directly into the knee joint for people with a persistent infection after knee replacement. It is for those whose infection is caused by certain bacteria and who are willing to stay in the hospital for 2 weeks.
Ürümqi, XinjiangAges 18 years+ - NCT06862453RecruitingPhase 1
Safety of a new malaria vaccine in healthy adults
This study tests a new malaria vaccine in healthy adults. You will receive the vaccine and then be exposed to the malaria parasite in a controlled setting to check if the vaccine protects you.
TübingenAges 18–45 - NCT06861543RecruitingPhase 1
TMT101 for advanced pancreatic or lung cancer
This trial tests a new drug called TMT101 for people with advanced pancreatic cancer or non-small cell lung cancer who have already tried other treatments. The goal is to see if TMT101 is safe and works against the cancer.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.